Your mammogram now reports breast density. Here is what that actually means.

If a recent mammogram report told you that you have dense breasts, it was flagging two real things at once: dense tissue is itself a risk factor for breast cancer, and it makes cancer harder to see on a mammogram [s2]. Since a US rule took effect in September 2024, mammography facilities are required to communicate this information to patients — but the notification raises a follow-up question that the evidence answers only with a trade-off [s1] [s3].

Why density is on the report at all

The Food and Drug Administration issued a final rule updating the national mammography regulations, published in March 2023 and effective on 10 September 2024, that modernised the standards in part by "strengthening the communication of healthcare information" and requiring facilities to provide patients with additional health information for more informed decision-making [s1]. Among the changes, as summarised in a medical-journal account of the rule, the FDA updated its breast-density reporting standards — making density notification a national requirement rather than the state-by-state patchwork it had been before [s3].

The medical rationale is straightforward. Breast density describes how much fibroglandular tissue, which appears white on a mammogram, a person has relative to fat, which appears dark. Cancers also appear white, so on a dense mammogram a tumour can be camouflaged. As the clinical literature puts it plainly, extremely dense breast tissue "is a risk factor for breast cancer and limits the detection of cancer with mammography" [s2]. Density is common — a substantial share of women have dense or extremely dense breasts — which is why the notification reaches so many people.

What the evidence says about doing more

The obvious next question is whether a woman with dense breasts should have additional screening beyond the mammogram. The best evidence comes from the DENSE trial, a randomised study in the Netherlands that assigned 40,373 women aged 50 to 75 with extremely dense tissue and a normal mammogram either to be invited for supplemental MRI or to continue with mammography alone [s2].

The benefit was real. The rate of interval cancers — cancers that surface between screening rounds, the ones a mammogram missed — was 2.5 per 1,000 screenings in the group invited for MRI, versus 5.0 per 1,000 in the mammography-only group, a halving (difference 2.5 per 1,000; 95% confidence interval 1.0 to 3.7; P<0.001) [s2]. Among the women who actually underwent MRI, the scan detected cancer at a rate of 16.5 per 1,000 screenings [s2].

The cost of that benefit was false alarms, and the trial quantified them rather than glossing over them. The false-positive rate was 79.8 per 1,000 screenings [s2]. Put differently, the positive predictive value — the chance that a flagged finding was actually cancer — was 17.4% for being recalled for more testing and 26.3% for proceeding to a biopsy [s2]. So most women sent for additional testing after an MRI did not have cancer, and a meaningful fraction of biopsies were negative. Notably, only 59% of women invited for MRI accepted [s2].

The trade-off the notification does not resolve

A density notification tells a woman she is in a higher-risk, harder-to-image group. It does not, by itself, tell her what to do — and the DENSE trial is why that is honest rather than evasive. Supplemental MRI finds cancers a mammogram misses and reduces the interval-cancer rate, but at the price of substantial over-recall and negative biopsies, and the trial studied specifically the "extremely dense" category and an older age range, not every woman who receives a density notice [s2]. Whether the trade favours more screening depends on a woman's overall risk, her tolerance for false alarms and further procedures, access and cost — a conversation, not a reflex.

The liftable summary: a breast-density notification is now a required, standardised piece of information, and it is legitimately useful, because density both raises risk and hides cancers. But the decision it invites — whether to add MRI or other imaging — is a genuine trade-off between catching more cancers early and enduring more false positives, and the evidence describes that trade-off rather than settling it for everyone.

This article is informational and is not medical advice. Decisions about supplemental breast screening should be made with a clinician who knows your individual risk.